Omnicell, Inc. (NASDAQ:OMCL) Shares Purchased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company grew its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 6.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 23,459 shares of the company’s stock after buying an additional 1,360 shares during the quarter. The Manufacturers Life Insurance Company owned 0.05% of Omnicell worth $635,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Arizona State Retirement System grew its holdings in Omnicell by 2.9% during the 2nd quarter. Arizona State Retirement System now owns 12,853 shares of the company’s stock worth $348,000 after acquiring an additional 357 shares in the last quarter. Texas Permanent School Fund Corp increased its stake in Omnicell by 1.2% in the 1st quarter. Texas Permanent School Fund Corp now owns 39,630 shares of the company’s stock valued at $1,158,000 after buying an additional 479 shares during the period. Diversified Trust Co lifted its position in shares of Omnicell by 3.3% in the second quarter. Diversified Trust Co now owns 15,364 shares of the company’s stock worth $416,000 after buying an additional 494 shares during the last quarter. Louisiana State Employees Retirement System increased its holdings in shares of Omnicell by 2.7% during the 2nd quarter. Louisiana State Employees Retirement System now owns 23,100 shares of the company’s stock valued at $625,000 after acquiring an additional 600 shares during the last quarter. Finally, ProShare Advisors LLC lifted its holdings in shares of Omnicell by 7.4% during the first quarter. ProShare Advisors LLC now owns 9,076 shares of the company’s stock worth $265,000 after buying an additional 626 shares during the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

OMCL has been the topic of several recent research reports. Benchmark reissued a “buy” rating and set a $48.00 price objective on shares of Omnicell in a report on Wednesday, October 9th. Wells Fargo & Company raised their price target on Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a research report on Monday. StockNews.com upgraded Omnicell from a “hold” rating to a “buy” rating in a report on Thursday, October 10th. JPMorgan Chase & Co. lifted their price target on Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a report on Friday, August 23rd. Finally, Barclays upgraded shares of Omnicell from an “underweight” rating to an “equal weight” rating and upped their price objective for the company from $26.00 to $39.00 in a report on Friday, August 2nd. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Omnicell has a consensus rating of “Moderate Buy” and an average price target of $41.33.

Omnicell Stock Performance

NASDAQ:OMCL opened at $42.38 on Wednesday. The firm has a market cap of $1.95 billion, a PE ratio of -92.13, a price-to-earnings-growth ratio of 47.35 and a beta of 0.83. Omnicell, Inc. has a fifty-two week low of $25.12 and a fifty-two week high of $45.84. The business has a 50 day moving average price of $43.12 and a 200-day moving average price of $34.04. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.22 and a current ratio of 2.45.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.37. The company had revenue of $276.80 million during the quarter, compared to analysts’ expectations of $254.41 million. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. Omnicell’s revenue was down 7.4% on a year-over-year basis. During the same period last year, the company posted $0.29 EPS. Equities research analysts predict that Omnicell, Inc. will post 0.64 earnings per share for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.